Actinium Announces Closing of Public Offering of Common Stock and Warrants to Purchase Common Stock
02 août 2017 16h05 HE
|
Actinium Pharmaceuticals
Actinium raised total gross proceeds of $16.125 million NEW YORK, Aug. 02, 2017 (GLOBE NEWSWIRE) -- Actinium Pharmaceuticals, Inc. (NYSE American:ATNM) ("Actinium" or "the Company"), a...
Actinium Announces Pricing of Public Offering of Common Stock and Warrants to Purchase Common Stock
28 juil. 2017 09h10 HE
|
Actinium Pharmaceuticals
NEW YORK, July 28, 2017 (GLOBE NEWSWIRE) -- Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) ("Actinium" or "the Company"), a biopharmaceutical company developing innovative targeted therapies for...
Actinium Announces Proposed Public Offering of Common Stock and Warrants to Purchase Stock
27 juil. 2017 16h05 HE
|
Actinium Pharmaceuticals
NEW YORK, July 27, 2017 (GLOBE NEWSWIRE) -- Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) ("Actinium" or "the Company"), a biopharmaceutical company developing innovative targeted therapies for...
Actinium Pharmaceuticals to Host Webinar Focused on Actimab-A and Recent Developments Related to CD33 Targeted AML Therapies on July 13, 2017 at 8:00 am ET
06 juil. 2017 07h30 HE
|
Actinium Pharmaceuticals
- Webinar topics will cover FDA Advisory Panel on Mylotarg, developments with other CD33 targeted therapies and update on Actimab-A - Webinar to be led by Dr. Joseph Jurcic, Director of Hematologic...
Actinium Pharmaceuticals Issues Mid-Year Letter to Shareholders Highlighting Accomplishments and Significant Value Enumerating Catalysts Over the Coming Quarters
15 juin 2017 08h30 HE
|
Actinium Pharmaceuticals
- Iomab-B Phase 3 SIERRA trial enrollment is accelerating as the number of clinical trial sites increase, competitive position as only induction and conditioning regimen remains unchallenged -...
Actinium Pharmaceuticals Announces Appointment of Nitya Ray, Ph.D. as Executive Vice-President, Head of Product Development, Manufacturing and Supply Chain and Other Key Hires in its Product Development and Manufacturing Teams
15 juin 2017 07h00 HE
|
Actinium Pharmaceuticals
- Dr. Nitya Ray joins Actinium Executive Team with 30 years of radiopharmaceutical and biologics product development, manufacturing and strategic planning experience - Also announced is the recent...
Actinium Pharmaceuticals to Host Webinar on June 12th to Update on Pivotal Phase 3 SIERRA Clinical Trial for Iomab-B
12 juin 2017 07h00 HE
|
Actinium Pharmaceuticals
Dr. Rajneesh Nath, a Principal Investigator and Director of the Bone Marrow Transplant and Acute Leukemia Program at Banner MD Anderson Cancer Center will discuss his perspectives on Iomab-B in...
Actinium Pharmaceuticals Announces Appointment of Sandesh Seth as Chief Executive Officer
09 juin 2017 07h30 HE
|
Actinium Pharmaceuticals
- Mr. Seth to serve as Chief Executive Officer and Chairman of the Board of Directors - Independent Director Dr. Ajit Shetty appointed to the Company’s Corporate Governance, Audit and Compensation...
Actinium Pharmaceuticals Highlights Presence at Upcoming Society of Nuclear Medicine and Molecular Imaging Annual Meeting
08 juin 2017 07h30 HE
|
Actinium Pharmaceuticals
- Society of Nuclear Medicine and Molecular Imaging to be held June 10 – 14, 2017 in Denver, Colorado - Actinium to conduct webinar to provide an update on its Pivotal Phase 3 drug...
UPDATE – Actinium Pharmaceuticals to Host Webinar on June 12th to Update on Pivotal Phase 3 SIERRA Clinical Trial for Iomab-B
08 juin 2017 07h00 HE
|
Actinium Pharmaceuticals
- Dr. Rajneesh Nath, a Principal Investigator and Director of the Bone Marrow Transplant and Acute Leukemia Program at Banner MD Anderson Cancer Center will discuss his perspectives on Iomab-B in...